Welcome to the Bioasis Technologies Hub On AGORACOM

Free
Message: XOMA Acquires Royalty Interest in Four Lysosomal Storage Disorder Enzymes Being Developed Under the Chiesi Group–Bioasis Strategic Alliance

As it stands right now, barring a buyout or some massive fantasy licensing agreement, the only way for this share price to appreciate materially is for management to take back control of its future.  That means find creative means to fund xb3-001 phase 1 as quickly as possible - that should be the #1 priority by far.

The xoma deal is a creative step in the right direction, but much more is needed to get this thing off the ground.

Share
New Message
Please login to post a reply